Acute Myeloid Leukemia Coverage From Every Angle
Advertisement
Advertisement

Clinical Implications of Condensing HDAC Regimen in Treatment of AML

By: Susan Reckling
Posted: Thursday, September 17, 2020

Christian Récher, MD, PhD, Head of the Hematology Department of the Institut Universitaire du Cancer de Toulouse, France, and colleagues retrospectively compared the delivery of high-dose cytarabine every 12 hours on days 1, 3, and 5 (HDAC-135)—the standard-of-care consolidation regimen for acute myeloid leukemia (AML)—with a condensed regimen on days 1, 2, and 3 (HDAC-123). In younger patients with AML in first response, although the condensed regimen appeared to induce a quicker hematologic recovery, with a related reduction in the length of hospital stay, it did not seem to affect treatment response or outcome. These study findings were published in Blood Advances.

“Patients receiving the HDAC-123 regimen spent 9 days less in the hospital over the whole period of postremission treatment,” commented the study authors. “Clinically relevant durations of leukopenia, neutropenia, and thrombocytopenia were significantly shortened by 3 to 4 days with the use of the HDAC-123 regimen compared with the HDAC-135 regimen.”

A total of 221 patients, with a median age of 46.6 years, were included in the study. As consolidation treatment in first complete response, HDAC-123 was given to 92 patients, and HDAC-135 was given to 129 patients.

The investigators observed similar rates of relapse-free survival, cumulative incidence of relapse, nonrelapsed mortality, and overall survival in both groups of patients. However, patients who received the condensed HDAC-123 regimen had a shorter hematologic recovery time (regarding neutrophils and platelets), with an average difference of between 3 and 4 days for each consolidation cycle. Furthermore, those given HDAC-123 had a shorter total duration of hospitalization for the entire postremission program than did that given HDAC-135 (32 vs. 42 days, P < .0001).

Disclosure: For full disclosures of the study authors, visit ashpublications.org.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.